Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Salk and Harvard scientists chart spinal circuitry responsible for chronic pain

December 3, 2014 – 5:00 pm | Edit Post

LA JOLLA–Pain typically has a clear cause–but not always. When a person touches something hot or bumps into a sharp object, it’s no surprise that it hurts. But for people with certain chronic pain disorders, including fibromyalgia and phantom limb pain, a gentle caress can result in agony.

Auspex Pharmaceuticals To Present At The Piper Jaffray Healthcare Conference

December 3, 2014 – 5:00 pm | Edit Post

LA JOLLA, Calif., Dec. 1, 2014 (GLOBE NEWSWIRE) — Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that Pratik Shah, Ph.D., President and Chief Executive…

Pathway Genomics Corporation Adds Former U.S. Congressman And Ambassador To Strategic Advisory Board

December 3, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that U.S. Congressman and Ambassador Tim Roemer has joined its strategic advisory board. A former U.S. ambassador to the Republic of India, Congressman Roemer holds a bachelors degree from the University of California San Diego…

Illumina Moving Forward With San Diego Expansion, 300 New Jobs

December 3, 2014 – 5:00 pm | Edit Post

Biocept, Inc. Appoints Experienced Physician As Medical Director

December 3, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) — Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced that Veena Singh, MD, FCAP, FCAMG has joined the Company as Senior Vice…

JAJ International, Inc. Release: Sierra Leone Pilot Study Of 10 Minute Ebola Rapid Test Shows Promise

December 3, 2014 – 5:00 pm | Edit Post

SAN DIEGO, CA–(Marketwired – December 02, 2014) – Medical diagnostic manufacturer JAJ International, Inc. (www.jajinternational.com) a subsidiary of LuSys Laboratories, Inc., receives promising results from a Sierra Leone Pilot Study for their Point of Care 10 Minute Ebola Rapid Test Diagnostic.On November 18th, the…

REVA Medical Implants First Patients With Fantom Scaffold

December 3, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 3, 2014 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) is pleased to announce it has initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. The first patient implants were performed by Dr. Alexandre Abizaid, Director…

Isis Pharmaceuticals, Inc. Release: ISIS-APOCIII Rx Phase 2 Study In Patients With Familial Chylomicronemia Published In The New England Journal of Medicine

December 3, 2014 – 5:00 pm | Edit Post

CARLSBAD, Calif., Dec. 3, 2014 /PRNewswire/ –Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from a Phase 2 study of ISIS-APOCIIIRx in patients with familial chylomicronemia syndrome (FCS) were published in The New England Journal of Medicine. The paper, titled “Targeting…

Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For Rayva In Patients With Raynaud’s Phenomenon

December 3, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 4, 2014 (GLOBE NEWSWIRE) — Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the first patient has been enrolled in the Phase 2a clinical trial to evaluate RayVa, Apricus…

Imprimis Pharmaceuticals Expands Proprietary Ophthalmic Formulations To Four Key Western States

December 3, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 3, 2014 /PRNewswire/ –Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, is expanding the availability of its Dropless formulations to over 3,000 ophthalmologists in four…